FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia

EPI-743 in two phase 2 development studies for Friedreich's ataxia MOUNTAIN VIEW, Calif., March 17, 2014 -- (Healthcare Sales & Marketing Network) -- Edison Pharmaceuticals today announced that the United States Food and Drug Administration granted Fas... BiopharmaceuticalsEdison Pharmaceuticals, EPI-743, Friedreich's ataxia, Vincerinone
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news